On target
5 April 2016

The United States is under fire for not doing more to prevent tax-reducing M&A deals. The $160 bln Pfizer-Allergan merger is a prime example. New rules seem to put it squarely in regulators’ sights. With the target’s shares down sharply, the Big Pharma tie-up looks under threat.